Grams ME, et al. - Given that eGFR decline represents a biologically plausible surrogate end point for CKD progression in clinical trials, researchers performed this random effects meta-analysis, wherein they examined participants with baseline eGFR≥60 ml/min per 1.73 m² (n=3,758,551) and participants with eGFR<60 ml/min per 1.73 m² (n=122,664) from 14 cohorts with an average follow-up of 4.2 years, to determine the link between 1-, 2-, and 3-year alterations in eGFR (slope) with clinical outcomes over the long term. Findings revealed a lower risk of subsequent ESKD, even in participants with eGFR≥60 ml/min per 1.73 m², in relation to slower decline in eGFR. However, the maximum benefit was expected to be seen in those with the highest risk.